PMID- 21930652
OWN - NLM
STAT- MEDLINE
DCOM- 20130305
LR  - 20120510
IS  - 1477-092X (Electronic)
IS  - 1078-1552 (Linking)
VI  - 18
IP  - 2
DP  - 2012 Jun
TI  - Enoxaparin once daily vs. twice daily dosing for the treatment of venous 
      thromboembolism in cancer patients: a literature summary.
PG  - 264-70
LID - 10.1177/1078155211412990 [doi]
AB  - Current anticoagulation guidelines for cancer patients are largely based upon 
      studies done in the general population. Anticoagulation studies in cancer 
      patients with venous thromboembolism (VTE) have compared varying doses of 
      different low molecular weight heparins (LMWH) to warfarin or unfractionated 
      heparin (UFH) regimens, and most guidelines recommend LMWH as the preferred agent 
      over vitamin K antagonists. However, very few studies compare different dosing 
      regimens of the LMWH itself. As a result, practitioners attempt to extrapolate 
      results from studies done in the general medicine population and apply them to 
      cancer patients with VTE. Considering the differences in risk factors and 
      hypercoagulability between these populations, such generalizations may compromise 
      outcomes or safety for cancer patients. Currently, no study to date has compared 
      the safety and efficacy of enoxaparin 1.5 mg/kg subcutaneously (SC) once daily 
      vs. 1 mg/kg SC twice daily in a prospective, randomized fashion, for the longterm 
      treatment of VTE in patients with cancer. The purpose of this article is to 
      review currently available literature utilizing these dosing schemes in order to 
      risk-stratify cancer patients who may better qualify for one dosing regimen as 
      compared to the other. Our analysis suggests that enoxaparin dosed at 1.5 mg/kg 
      SC once daily may be a safe and effective alternative for the treatment of VTE in 
      cancer patients with both a low risk of recurrent VTE and bleeding. In the 
      absence of additional studies, the dosing of enoxaparin for cancer patients 
      should be based on patient-specific risk factors.
FAU - Diaz, Amber H
AU  - Diaz AH
AD  - Southwest Washington Medical Center, Department of Pharmacy Services, Vancouver, 
      WA, Canada.
FAU - Rodgers, George M
AU  - Rodgers GM
FAU - Gilreath, Jeffrey A
AU  - Gilreath JA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110919
PL  - England
TA  - J Oncol Pharm Pract
JT  - Journal of oncology pharmacy practice : official publication of the International 
      Society of Oncology Pharmacy Practitioners
JID - 9511372
RN  - 0 (Enoxaparin)
SB  - IM
MH  - Clinical Trials as Topic/methods
MH  - Drug Administration Schedule
MH  - Enoxaparin/*administration & dosage
MH  - Humans
MH  - Neoplasms/*drug therapy/epidemiology
MH  - Treatment Outcome
MH  - Venous Thromboembolism/*drug therapy/epidemiology
EDAT- 2011/09/21 06:00
MHDA- 2013/03/06 06:00
CRDT- 2011/09/21 06:00
PHST- 2011/09/21 06:00 [entrez]
PHST- 2011/09/21 06:00 [pubmed]
PHST- 2013/03/06 06:00 [medline]
AID - 1078155211412990 [pii]
AID - 10.1177/1078155211412990 [doi]
PST - ppublish
SO  - J Oncol Pharm Pract. 2012 Jun;18(2):264-70. doi: 10.1177/1078155211412990. Epub 
      2011 Sep 19.